300878 Zhejiang Wecome Pharmaceutical
- 14.47
- +0.25+1.76%
Zhejiang Wecome Pharmaceutical News
Weikang Pharmaceutical: 2024 Semi-Annual Report
Weikang Pharmaceutical: 2024 Semi-Annual Report Summary
Zhejiang Wecome Pharmaceutical (300878.SZ) announced its performance for the first half of the year, with a net income of 14.1921 million yuan, a decrease of 78.04%.
Zhejiang Wecome Pharmaceutical (300878.SZ) released its 2024 interim report, with a revenue of 0.297 billion...
Express News | Zhejiang Wecome Pharmaceutical: net income of 14.1921 million yuan in the first half of the year, a year-on-year decrease of 78.04%.
Express News | Zhejiang Wecome Pharmaceutical: Net income in the first half of 2024 decreased by 78.04% year-on-year.
Zhejiang Wecome Pharmaceutical (300878.SZ): Currently, there is no drug available to treat monkeypox.
Zhejiang Wecome Pharmaceutical (300878.SZ) stated on the investor interaction platform on August 21 that the company currently has no drugs for treating monkeypox.
Traditional Chinese medicine stocks in A-shares continue to strengthen, xiangxue pharmaceutical has two consecutive boards.
On August 1, Gelunhui reported that Xiangxue Pharmaceutical has risen for two consecutive days, while Wecome Pharmaceutical increased by over 10%. Guangdong Jiangxi Wannianqing Cement, Zhejiang Xinguang Pharmaceutical, Mayinglong Pharmaceutical Group, China Resources Sanjiu Medical & Pharmaceutical followed the trend.
Express News | Zhejiang Wecome Pharmaceutical plans to transfer the entire equity of its wholly-owned subsidiary Wecome Retail and Wecome Pharmacy.
Zhejiang Wecome Pharmaceutical Co., Ltd. (300878.SZ) plans to sell 100% equity of Vicom Retail and Vicom Pharmacy, focusing on pharmaceutical manufacturing.
Zhejiang Wecome Pharmaceutical (300878.SZ) announced that the company intends to transfer 100% equity of its wholly-owned subsidiary, Vicom Retail, to Fuku...
Express News | Zhejiang Wecome Pharmaceutical: plans to transfer the equity of its wholly-owned subsidiary.
Express News | Zhejiang Wecome Pharmaceutical received the summary report of Phase IIb clinical trial of silver and yellow pellets.
Express News | Zhejiang Wecome Pharmaceutical: Once again extended reply to the annual report letter of inquiry to June 21, 2024.
Weikang Pharmaceutical (300878.SZ) and related personnel received a warning letter from Zhejiang Securities Regulatory Bureau
Weikang Pharmaceutical (300878.SZ) announced that the company and relevant responsible personnel received it on May 27, 2024...
Focusing on the pharmaceutical manufacturing industry, Weikang Pharmaceutical (300878.SZ) plans to sell 2 retail chain business subsidiaries
Weikang Pharmaceutical (300878.SZ) announced that Zhejiang Weikang Pharmaceutical Commercial Co., Ltd., a wholly-owned subsidiary of the company (“Weikang...
Express News | Weikang Pharmaceutical: Wholly-owned subsidiary Weikang Commercial plans to sell 100% of the shares in Weikang Retail and Weikang Pharmacy
Express News | Performance forecasting was not carried out within 1 month from the end of the fiscal year in accordance with regulations. Weikang Pharmaceutical received a regulatory letter from the Shenzhen Stock Exchange when it was appointed as chairman, etc.
Weikang Pharmaceutical (300878.SZ) plans to pay 2.5 yuan for 10 shares to be deducted from interest on May 29
Weikang Pharmaceutical (300878.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Weikang Pharmaceutical (300878.SZ): Elected Liu Yang as Chairman of the 4th Board of Directors of the Company
Gelonghui, May 21, 丨 Weikang Pharmaceutical (300878.SZ) announced that on May 20, 2024, the first meeting of the fourth board of directors deliberated and agreed to elect Liu Yang as the chairman of the fourth board of directors for a term of three years, from the date of review and approval of the current board of directors until the end of the term of the fourth board of directors.
Weikang Pharmaceutical (300878.SZ) announced its 2023 annual results, with a net loss of 8.038,600 yuan, a year-on-year profit to loss
According to the Zhitong Finance App, Weikang Pharmaceutical (300878.SZ) released its 2023 annual report. The company achieved revenue of 520 million yuan during the reporting period, a decrease of 2.41% over the previous year. The net loss attributable to shareholders of the listed company was RMB 8,038,600, a year-on-year change of profit to loss. The net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was 25.217,500 yuan, a year-on-year profit to loss. Basic earnings per share - 0.06 yuan/share, and it is proposed to distribute a cash dividend of 2.50 yuan (tax included) for every 10 shares to all shareholders.
Express News | Weikang Pharmaceutical: Net profit of 243.35 million yuan in the first quarter decreased 11.6% year on year
Analysis
Price Target
No Data
